104 episodes

The Blood Podcast will summarize content recently published in Blood the most cited peer-reviewed publication in the field of hematology.

Blood Podcast American Society of Hematology

    • Science
    • 4.2 • 31 Ratings

The Blood Podcast will summarize content recently published in Blood the most cited peer-reviewed publication in the field of hematology.

    Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation

    Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation

    In this week’s episode, we review results of preclinical investigations that sound a note of caution regarding the potential use of JAK inhibitors as treatment for hemophagocytic lymphohistiocytosis (or HLH), research that provides new insights on how CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax, and conclude with a report that demonstrates cooperation between B cell receptor signaling and genetic lesions in CDKN2A, CDKN2B and TP53 in Richter transformation.

    • 15 min
    Improved risk assessment in adult BCR-ABL1-negative B-ALL, value of clone metrics in clonal cytopenias, a placental protease generates a peptide to inhibit NET formation

    Improved risk assessment in adult BCR-ABL1-negative B-ALL, value of clone metrics in clonal cytopenias, a placental protease generates a peptide to inhibit NET formation

    In this week’s episode, we will review an integrated analysis of one of the largest adult BCR-ABL1-negative B-ALL patient cohorts treated in a single trial, learn more about the genotypic and phenotypic features of patients with clonal cytopenias, and look at a study showing that a serine protease expressed in the placenta cleaves α1-antitrypsin to generate a fragment that inhibits formation of neutrophil extracellular traps in neonates.

    • 17 min
    Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS

    Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS

    In this week’s episode, we’ll review updated results of a phase 1b study that provide strong support for the use of fixed-duration venetoclax in patients with relapsed or refractory CLL. Next, we’ll review a research paper that provides new insights on the different subtypes of invariant natural killer T cells, which appear to have diverse immunoregulatory properties and anti-tumor effects. We will finish up with a report indicating that rare variants in the telomerase gene, TERT, are underrecognized in patients with myelodysplastic syndromes, providing a new insight into the germline genetic component of disease pathophysiology.

    • 22 min
    Activated BCL11B in acute leukemias, SARS-CoV-2 antibody responses in lymphoma patients receiving B-cell therapies, and PD-L1 in neutrophil apoptosis and tissue inflammation

    Activated BCL11B in acute leukemias, SARS-CoV-2 antibody responses in lymphoma patients receiving B-cell therapies, and PD-L1 in neutrophil apoptosis and tissue inflammation

    In this week’s episode, we will review a study that shows that BCL11B is an important oncogene in acute leukemias with myeloid and T-lymphoid features, learn more about antibody responses to SARS-CoV-2 vaccination in lymphoma patients receiving B-cell directed therapies, and examine the role of programmed death ligand 1 (or PD-L1) and the PI 3 kinase-AKT survival pathway in delayed neutrophil apoptosis at sites of tissue inflammation.

    • 17 min
    Blood Review Series on Mechanisms of Hematologic Malignancies

    Blood Review Series on Mechanisms of Hematologic Malignancies

    To reach the goal of curing currently incurable hematologic malignancies, we need to go beyond focusing on single gene mutations and gain deeper understanding of the consequences of genetic alterations on gene-regulatory pathways. Edited by John Crispino, these 5 cutting-edge reviews from leaders in the their fields not only summarize our current understanding of key pathways that contribute to myeloid malignancies, but also discuss new therapeutic avenues related to them. They provide a springboard for further groundbreaking basic and clinical advances in hematologic malignancies.

    • 28 min
    IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia

    IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia

    In this week's episode, we will review a study that proposes IFN-λ therapy as a novel strategy to boost gut protection in GvHD, examine the immunomodulatory effects of decitabine in ITP, and learn about the discovery of TET2 mutations in chronic natural killer large granular lymphocyte leukemia

    • 18 min

Customer Reviews

4.2 out of 5
31 Ratings

31 Ratings

MMTG1988 ,

Blood podcasts

Please podcast detailed narratives of clinical review articles and how I treat series. For busy hematologists, pressure of electric records taking away time for self education, catching up on latest articles while driving is a welcome relief.

Masonjaren ,

Bedtime stories

Needs to be delivered conversationally or w/ dedicated interviews w/ authors (e.g. NEJM this week pod).

TomCityofHope ,

Needs to be more interesting

It is great information but it needs to be presented in a more engaging fashion ( maybe conversational vs just reading the data results). Some episodes put me to sleep

Top Podcasts In Science

Listeners Also Subscribed To